Burzynski Research Institute (BZYR) Shares Outstanding (2010 - 2025)
Burzynski Research Institute (BZYR) posted Shares Outstanding (Entity) of $131.4 million for Q4 2025, little changed sequentially from $131.4 million in Q3 2025, and little changed YoY from $131.4 million in Q4 2024.
Burzynski Research Institute (BZYR) Shares Outstanding (2010 - 2025) Analysis & Trends
Burzynski Research Institute has reported Shares Outstanding (Entity) for 16 years, with the latest figure at $131.4 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) changed 0.0% year-over-year to $131.4 million in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $131.4 million (changed 0.0% YoY) and the FY2025 annual result came in at $131.4 million, changed 0.0% from the prior year.
- Shares Outstanding (Entity) held at $131.4 million in Q4 2025 per BZYR's latest filing, from $131.4 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $131.4 million in Q1 2021 and troughed at $131.4 million in Q1 2021.
- A 5-year average of $131.4 million and a median of $131.4 million in 2021 frame the typical range for Shares Outstanding (Entity).
- The widest YoY moves for Shares Outstanding (Entity): up 0.0% in 2021, down 0.0% in 2021.
- Over 5 years, Shares Outstanding (Entity) stood at $131.4 million in 2021, then changed by 0.0% to $131.4 million in 2022, then changed by 0.0% to $131.4 million in 2023, then changed by 0.0% to $131.4 million in 2024, then changed by 0.0% to $131.4 million in 2025.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $131.4 million, $131.4 million, and $131.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | 131.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 131.45 Mn |
| Aug 31, 2025 | 131.45 Mn |
| May 31, 2025 | 131.45 Mn |
| Feb 28, 2025 | 131.45 Mn |
| Nov 30, 2024 | 131.45 Mn |
| Aug 31, 2024 | 131.45 Mn |
| May 31, 2024 | 131.45 Mn |
| Feb 29, 2024 | 131.45 Mn |
| Nov 30, 2023 | 131.45 Mn |
| Aug 31, 2023 | 131.45 Mn |
| May 31, 2023 | 131.45 Mn |
| Feb 28, 2023 | 131.45 Mn |
| Nov 30, 2022 | 131.45 Mn |
| Aug 31, 2022 | 131.45 Mn |
| May 31, 2022 | 131.45 Mn |
| Feb 28, 2022 | 131.45 Mn |
| Nov 30, 2021 | 131.45 Mn |
| Aug 31, 2021 | 131.45 Mn |
| May 31, 2021 | 131.45 Mn |
| Feb 28, 2021 | 131.45 Mn |